This intranasal siGal-1 delivery induced a dramatic alteration in the composition of the tumor microenvironment (TME), including a decrease in myeloid suppressor cells and regulatory T cells, and an increase in CD4+ and CD8+ T cells, during the progression of GBM. The gene discussed is CD8A; the disease is glioblastoma.